Werlinich Asset Management LLC Invests $1.06 Million in Novo Nordisk A/S (NYSE:NVO)

Werlinich Asset Management LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 12,305 shares of the company’s stock, valued at approximately $1,055,000.

Several other large investors have also recently bought and sold shares of NVO. International Assets Investment Management LLC raised its position in shares of Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after buying an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC raised its holdings in Novo Nordisk A/S by 257,816.0% in the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after acquiring an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $98,765,000. Marshall Wace LLP grew its holdings in shares of Novo Nordisk A/S by 34,472.1% during the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after purchasing an additional 689,441 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at $42,017,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of analyst reports. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Stock Up 0.4 %

Shares of NYSE NVO opened at $83.26 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $373.61 billion, a PE ratio of 26.94, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The firm’s 50-day moving average is $98.82 and its 200-day moving average is $117.93. Novo Nordisk A/S has a 1 year low of $80.05 and a 1 year high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.